PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

Bar Kaufman; Tarek Taha; Orli Abramov; Yaniv Zohar; Kamel Mhameed; Ofir Cohen; Angel Porgador; Moshe Elkabets; Salem Billan

doi:10.1038/s41698-024-00620-y

PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

Bar Kaufman
, Tarek Taha
, Orli Abramov
, Yaniv Zohar
, Kamel Mhameed
, Ofir Cohen
, Angel Porgador
, Moshe Elkabets
, Salem Billan

The Shraga Segal Department of Microbiology and Immunology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands’ functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

Original language	English
Article number	126
Journal	npj Precision Oncology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/s41698-024-00620-y
State	Published - 1 Dec 2024

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41698-024-00620-y

Cite this

@article{017f3fddc2ba495dbd216ff806065f0b,

title = "PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC",

abstract = "Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands{\textquoteright} functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.",

author = "Bar Kaufman and Tarek Taha and Orli Abramov and Yaniv Zohar and Kamel Mhameed and Ofir Cohen and Angel Porgador and Moshe Elkabets and Salem Billan",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

day = "1",

doi = "10.1038/s41698-024-00620-y",

language = "English",

volume = "8",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

AU - Kaufman, Bar

AU - Taha, Tarek

AU - Abramov, Orli

AU - Zohar, Yaniv

AU - Mhameed, Kamel

AU - Cohen, Ofir

AU - Porgador, Angel

AU - Elkabets, Moshe

AU - Billan, Salem

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands’ functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

AB - Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands’ functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

UR - https://www.scopus.com/pages/publications/85195270152

U2 - 10.1038/s41698-024-00620-y

DO - 10.1038/s41698-024-00620-y

M3 - Article

C2 - 38830971

AN - SCOPUS:85195270152

SN - 2397-768X

VL - 8

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 126

ER -

PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this